Park Medi World Limited enters Q1 FY 2026-2027 following a record-breaking year, as the hospital chain navigates the early-season surge in vector-borne diseases and the implementation of revised government health scheme rates. Investors will be looking for updates on the occupancy ramp-up at the newly commissioned Panchkula facility and the margin impact of recent strategic acquisitions.
| Results date | August 03, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Previous quarter revenue | Rs. 460.4 Cr |
| Previous quarter PAT | Rs. 76.8 Cr |
| Previous quarter EBITDA margin | 27.7% |
| Net debt (latest quarter) | Rs. 28 Cr |
| Market cap | Rs. 12,083.27 Cr |
| CMP | Rs. 279.25 |
The board meeting is scheduled for August 3, 2026, to consider the standalone and consolidated unaudited financial results for the quarter ending June 30, 2026.
A conference call for analysts and institutional investors is scheduled for Tuesday, August 4, 2026, at 09:00 am IST to discuss the Q1 FY27 results.
The hospital chain is positioned for strong sequential growth in Q1 FY27, driven by the 350-bed Panchkula facility commissioned on April 10, 2026, and an early, intense seasonal surge in dengue and flu cases. Management's guidance for FY27 incorporates a 7.5% incremental EBITDA benefit from the recently revised CGHS rates, which covered 83% of the patient mix as of December 31, 2025. While new assets like the 360-bed Agra unit currently operate at 30% occupancy, they are central to the company's strategy to reach 5,460 beds by March 2028. The upcoming call will likely focus on the margin trajectory as these new facilities ramp up, alongside updates on debtor days, which stood at 129 days at the close of FY26.
Performance vs Guidance Tracking
Panchkula Facility Ramp-Up
Acquisitions Integration Update
Risks and headwinds to monitor
Revenue from operations stood at Rs. 460.4 Cr in Q4 FY26, representing 30% YoY growth from Rs. 353.9 Cr in Q4 FY25.
Management successfully reduced net debt to a negligible Rs. 28 Cr by March 31, 2026, following post-IPO debt repayment. The company now intends to fund its next phase of expansion entirely through internal accruals.
The company aims to grow from 3,610 beds in FY26 to 5,460 beds by FY28, with 16 hospitals currently operational. Recent additions include the 350-bed Panchkula facility commissioned in April 2026.
Yes, the company achieved a 26.5% EBITDA margin in FY26, which is within its long-term guided range of 26-27%. Additionally, the target to become debt-free was achieved by February 2026.
Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings
Login Now